References
- Belli Hasan, Ural Cenk, Akbudak Mahir: Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment, J Clin Med Res. 2012, 4(5):301–8.
- Bellino Silvio, Paradiso Erika, Bogetto Filippo, Efficacy and tolerability of pharmacotherapies for borderline personality disorder, CNS Drugs 2008, 22(8):671–92.
- Bellino Silvio, Paradiso Erika, Bogetto Filippo, Oxcarbazepine in the treatment of borderline personality disorder: a pilot study, J Clin Psychiatry 2005, 66(9):1111–5.
- Bozzatello Paola, Garbarini Claudia, Rocca Paola, et al., Borderline Personality Disorder: Risk Factors and Early Detection; Diagnostics 2021, 11(11): 2142.
- Chapman Jennifer, Jamil T. Radia, Fleisher Carl, Borderline Personality Disorder, Treasure Island (FL): StatPearls Publishing; 2024, p. 9–10.
- https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinalproducts/31472/characteristic, s. 2–10.
- Cristea A. Ioana, Gentili Caterina, Cotet D. Carmen, et al., Efficacy of Psychotherapies for Borderline Personality Disorder: A Systematic Review and Meta-analysis, JAMA Psychiatry 2017, 74:319.
- Gartlehner Gerald, Crotty Karen, Kenned Sara, et. al., Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis, CNS Drugs 2021, 35(10):1053–1067.
- Grant M. Susan, Faulds Diana, Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders, Drugs 1992, 43(6):873–88.
- Have Ten Margreet, Verheul Roel, Kaasenbrood Ad, et al., Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands Mental Health Survey and Incidence Study-2, BMC Psychiatry 2016, 16: 249.
- https://go.drugbank.com/drugs/DB00776.
- Huband Nick, Ferriter Michael, Nathan Rajan, et al., Antiepileptics for aggression and associated impulsivity, Cochrane Database Syst Rev. 2010, 2010(2):CD003499.
- Ingenhoven Theo, Lafay Patricia, Rinne Thomas, et al., Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials, J Clin Psychiatry 2010, 71(1):14–25.
- McGlashan H. Thomas, Grilo M. Carlos, Skodol E. Andrew, et al., The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence, Acta Psychiatrica Scand 2000, 102(4):256–64.
- Międzynarodowa Statystyczna Klasyfikacja Chorób i Problemów Zdrowotnych, Rewizja dziesiąta (ICD-10), kod F60.3 (Osobowość chwiejna emocjonalnie).
- Sieberer Marcel, Emrich M. Hinderk, [Empirical evidence for the use of anticonvulsants in personality disorders], Fortschr Neurol Psychiatr. 2009, 77(3):133–8.
- Stoffers Jutta, Völlm A Birgit, Rücker Gerta, et al., Pharmacological interventions for borderline personality disorder,; Cochrane Database Syst Rev. 2010, 16:(6):CD005653.
- Stoffers-Winterling M. Jutta, Storeba J. Ole, Kongerslev T. Mickey, et al., Psychotherapies for borderline personality disorder: a focused systematic review and meta-analysis, Br J Psychiatry 2022, 221:538.
- Wedig M. Michelle, Silverman H. Merav, Frankenburg R. Frances, et al., Predictors of suicide attempts in patients with borderline personality disorder over 16 years of prospective follow-up, Psychol. Med. 2012, 42(11): 2395–2404.